QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Geoerger, B. Articles by Phillips, P. C. Search for Related Content PubMed PubMed Citation

Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts

Children's Hospital of Philadelphia, Division of Neuro-oncology (B.G., C.-B.T., P.C.P.) and Department of Neurosurgery (S.M., L.N.S.), Philadelphia, PA 19104; and The Wistar Institute (A.C., S.V., D.S.), Hospital of the University of Pennsylvania, Department of Neurosurgery (K.D.J.), Philadelphia, PA 19104

² Address correspondence and reprint requests to Peter C. Phillips, Children's Hospital of Philadelphia, Division of Neuro-Oncology, 3400 Civic Center Boulevard, Philadelphia, PA 19104.

Abstract

Malignant glioma in adults and primitive neuroectodermal tumors/medulloblastomas in children are the most common malignant primary brain tumors that either respond poorly to current treatment or tend to recur. Adoptive therapy with TALL-104 cells—an IL-2-dependent, major histocompatibility complex nonrestricted, cytotoxic T-cell line—has demonstrated significant antitumor activity against a broad range of implanted or spontaneously arising tumors. This study investigates distribution of systemically and locally administered TALL-104 cells and their efficacy in effecting survival of a rat model of human brain tumor. In vitro, TALL-104 cells showed significant cytotoxic activity when added to human glioblastoma cell lines U-87 MG, U-251 MG, and A1690; the medulloblastoma cell lines DAOY, D283 Med, and D341 Med; and the epidermoid cancer cell line A431. In brain tumor-bearing rats, the amount of fluorescent dye-labeled TALL-104 cells in brain increased after they were given by intracarotid injection as compared with i.v. cell administration. However, TALL-104 cells rapidly decreased to low levels within 1 h after intracarotid injection. This finding suggests that TALL-104 cells given systemically may not invade brain or tumor tissues, but rather may remain in the vascular system, making this approach less efficient for brain tumor treatment. In a model of athymic rats engrafted with human A431 carcinoma brain tumor, repetitive local administration of TALL-104 cells directly into the tumor bed resulted in a significant increase in survival time compared with control animals. Therefore, local therapy with TALL-104 cells may be a novel and highly effective treatment approach for malignant brain tumors.

This article has been cited by other articles:

				C. Brando, S. Mukhopadhyay, E. Kovacs, R. Medina, P. Patel, T. L. Catina, K. S. Campbell, and D. Santoli Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104 J. Leukoc. Biol., August 1, 2005; 78(2): 359 - 371. [Abstract] [Full Text] [PDF]

				G. G. Gomez, S. B. Read, L. E. Gerschenson, D. Santoli, A. Zweifach, and C. A. Kruse Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors Neuro-oncol, April 1, 2004; 6(2): 83 - 95. [Abstract] [PDF]